CANbridge Pharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	62.56	85.1	102.87	78.97	31.16	12.03
Revenue Growth (YoY)	-40.20%	-17.27%	30.26%	153.43%	158.98%	719.06%
Cost of Revenue	22.27	30.8	38.71	30.08	12.39	5.15
Gross Profit	40.29	54.3	64.16	48.89	18.78	6.88
Selling, General & Admin	106.92	143.06	173.5	195.69	246.27	128.72
Research & Development	96.5	251.76	257.21	311.17	427.66	109.64
Operating Expenses	203.41	394.82	430.71	506.86	673.92	238.37
Operating Income	-163.13	-340.52	-366.55	-457.97	-655.15	-231.49
Interest Expense	-5.78	-8.58	-8.95	-6.86	-3.08	-3.79
Interest & Investment Income	0.07	0.51	10.98	3.89	2.61	0.96
Currency Exchange Gain (Loss)	-	-	-	-	0.63	-
Other Non Operating Income (Expenses)	11.75	-12.56	-14.56	-22.97	30.69	-22.03
EBT Excluding Unusual Items	-157.09	-361.15	-379.08	-483.91	-624.3	-256.35
Gain (Loss) on Sale of Assets	7.88	6.5	-	0.44	9.73	-
Asset Writedown	-87.99	-87.99	-	-	-	-
Other Unusual Items	101.08	0.03	0.24	-	-462.44	-589.7
Pretax Income	-136.11	-442.62	-378.84	-483.48	-1,077	-846.04
Net Income	-136.11	-442.62	-378.84	-483.48	-1,077	-846.04
Net Income to Common	-136.11	-442.62	-378.84	-483.48	-1,077	-846.04
Shares Outstanding (Basic)	425	425	424	424	94	69
Shares Outstanding (Diluted)	425	425	424	424	94	69
Shares Change (YoY)	0.05%	0.11%	0.04%	350.13%	37.39%	0.12%
EPS (Basic)	-0.32	-1.04	-0.89	-1.14	-11.43	-12.33
EPS (Diluted)	-0.32	-1.04	-0.89	-1.14	-11.43	-12.33
Free Cash Flow	-23.02	-122.5	-283.38	-296.18	-592.16	-154.22
Free Cash Flow Per Share	-0.05	-0.29	-0.67	-0.70	-6.28	-2.25
Gross Margin	64.40%	63.81%	62.37%	61.91%	60.26%	57.16%
Operating Margin	-260.76%	-400.12%	-356.32%	-579.91%	-2102.46%	-1923.94%
Profit Margin	-217.58%	-520.10%	-368.26%	-612.21%	-3456.26%	-7031.61%
Free Cash Flow Margin	-36.80%	-143.94%	-275.47%	-375.04%	-1900.31%	-1281.74%
EBITDA	-150.2	-326.8	-354.72	-448.84	-646.11	-217.13
D&A For EBITDA	12.93	13.72	11.82	9.13	9.04	14.36
EBIT	-163.13	-340.52	-366.55	-457.97	-655.15	-231.49

Source: S&P Global Market Intelligence. Standard template. Financial Sources.